Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).

Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). Eur J Cancer. 2021 08; 153:223-233.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Capecitabine
Female
Humans
Middle Aged
Oxazoles
Pyridines
Quality of Life
Quinazolines
Receptor, ErbB-2
Trastuzumab
Treatment Outcome
Young Adult

authors with profiles

Olwen Hahn